GlassScriptPhysician profile
William S Haaz
NPI 1366445322
$8,181.10
in general payments reported to CMS, 2019-2025
37 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $427 · 2021: $765 · 2022: $1,091 · 2023: $1,391 · 2024: $1,367 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,961 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,960.58 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,348.88 | 2019-2023 | Xarelto |
| Pfizer INC. | $1,052.71 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $888.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $818.90 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $710.86 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $476.07 | 2019-2025 | Watchman Access System, Cds - Mct/Cem Monitoring |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.62 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $303.97 | 2019-2025 | Wainua, Farxiga |
| Alnylam Pharmaceuticals INC. | $277.27 | 2023-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $239.38 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $233.64 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $163.03 | 2023-2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.74 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $120.37 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $114.09 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.51 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $83.27 | 2021-2025 | |
| Astellas Pharma US INC | $74.58 | 2019-2021 | |
| Abbott Laboratories | $72.60 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Edwards Lifesciences Corporation | $65.73 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Inspire Medical Systems, INC. | $55.38 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $51.95 | 2024 | Arcalyst |
| Ge Healthcare | $47.18 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $44.97 | 2023 | Arcalyst |
| Bridgebio Pharma, INC. | $34.57 | 2025 | Attruby |
| Scpharmaceuticals INC. | $32.72 | 2023-2024 | |
| Althera Pharmaceuticals LLC | $32.01 | 2021 | |
| Endotronix, INC. | $30.11 | 2024 | Cordella Pulomonary Artery Pressure Sensor |
| Portola Pharmaceuticals, LLC | $24.46 | 2020 | |
| Philips North America LLC | $24.22 | 2024 | (Ck4) Mcot |
| Daiichi Sankyo INC. | $21.52 | 2019 | |
| Vital Connect, INC | $21.34 | 2025 | Vitalpatch Rtm |
| Regeneron Healthcare Solutions, INC. | $20.31 | 2025 | Evkeeza |
| Akcea Therapeutics, INC. | $18.58 | 2020 | |
| Watermark Medical, INC. | $18.40 | 2024 | |
| Medicomp INC | $14.67 | 2024 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Haaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.